Dale Bredesen, M.D.
An internationally-recognized expert in the mechanisms of neurodegenerative diseases, Dr. Dale Bredesen’s career has been guided by a simple idea: that Alzheimer’s as we know it is not just preventable, but reversible. Thanks to a dedicated pursuit of finding the science that makes this a reality, his idea has placed Dr. Bredesen at the vanguard of neurological research, and led to the discoveries that today underlie the ReCode Report.
Dr. Bredesen earned his MD from Duke University Medical Center and served as Chief Resident in Neurology at the University of California, San Francisco (UCSF) before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA and the University of California, San Diego. Dr. Bredesen also directed the Program on Aging at the Burnham Institute before joining the Buck Institute in 1998 as founding President and CEO.
Dr. Bredesen’s research explores previously uncharted territory in explaining the physical mechanism behind the erosion of memory seen in Alzheimer’s disease, and has opened the door to new approaches to treatment. This work has led to the identification of several new therapeutic processes that are showing remarkable
Dr. Bredesen is a prodigious innovator in medicine, with over thirty patents to his name. Notably, he put much of his finding and research into the 2017 New York Times best-seller The End of Alzheimer’s.